The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.
The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets. The grants are part of NIH’s Big Data to Knowledge (BD2K) initiative, launched in December 2013. BD2K is funded from all 27 NIH institutes and centers, as well as the NIH Common Fund.
According to NIH, the collection of data from biomedical research, including DNA sequencing and imaging, is increasing beyond researchers’ ability to use the data. NIH intends for the BD2K awards to “support the development of new approaches, software, tools, and training programs to improve access to these data and the ability to make new discoveries using them.”
“Data creation in today’s research is exponentially more rapid than anything we anticipated even a decade ago,” said NIH Director Francis S. Collins, MD, PhD, in a press release. “Mammoth data sets are emerging at an accelerated pace in today’s biomedical research and these funds will help us overcome the obstacles to maximizing their utility. The potential of these data, when used effectively, is quite astounding.”
NIH funding will establish 12 centers that will each tackle specific data science challenges and provide support for creating a scientific community-based consortium to develop approaches for the creation of a data discovery index, data science training, and workforce development. The centers will be set up as follows:
More information about the recipients of the new grants may be found on NIH’s website at http://bd2k.nih.gov/FY14.html.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.